Market News & Trends
Cellectar Biosciences Announces Pricing of $3.3 Million Financing
Cellectar Biosciences, Inc. recently announced the pricing of a registered direct offering of 1,017,272 shares of its common stock and Series B pre-funded warrants to…
AAA Announces Positive Results From Phase III Study
Advanced Accelerator Applications S.A. recently announced that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its primary endpoint of assessing progression-free survival (PFS),…
Bayer Receives FDA Approval for First & Only Electronic Autoinjector in RRMS Treatment
Bayer HealthCare recently announced the US FDA approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will…
Genisphere Closes $4 Million for Expansion of 3DNA Targeted Drug Delivery Platform
Genisphere LLC recently announced it has closed a $4-million equity round. This round of fundraising will extend and expand development of Genisphere's targeted drug delivery…
Vetter Embarks on a 300 Million Euro Investment Strategy
Ravensburg, Germany, September 30, 2015 – Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug…
Ultra-Low Flow Technology for Drug Delivery
FARMINGTON, CT (September 2015) – Mott Corporation has developed a technology that controls the flow rate of a liquid or drug in devices over…
Xcelience & Powdersize Add Delta Vita Nano-Milling
Xcelience and Powdersize recently announced the addition of the Netzsch Delta Vitamedia mills, a nanoparticle milling solution, to their arsenal of capabilities. For the first…
Nemera’s Next-Generation Nasal Spray Now in Production
Nemera has invested more than 10 million euros in R&D and manufacturing to launch the only user-independent multi-dose nasal spray system on the market. So…
Scholar Rock Presents First Data, Announces Lead Drug Program
Scholar Rock recently announced that SRK-015 is the company’s lead drug development candidate, a niche modulator inhibiting activation of the latent myostatin precursor. The announcement…
RegeneRx Announces First Patient Enrolled in Phase III Trial
RegeneRx Biopharmaceuticals, Inc. recently announced the first patient has been enrolled in a Phase III clinical trial with RGN-259 (designated GBT-201 in Korea), its sterile,…
Deciphera Pharmaceuticals Announces $75-Million Financing
Deciphera Pharmaceuticals recently announced it has closed a $75-million Series B financing led by New Leaf Venture Partners and joined by Deciphera’s existing investors. The…
BIND Therapeutics Announces Pfizer Exercises Option
BIND Therapeutics, Inc. recently announced Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the…
Oncology Leads Development in Promising Gene Therapy Pipeline
Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development…
Drug Development & Delivery to Launch Innovation Networking Event
Drug Development & Delivery President & Publisher Ralph Vitaro recently announced that the leading media company will be hosting the inaugural Innovation Networking Summit &…
Dimension Therapeutics Announces FDA Fast Track Designation
Dimension Therapeutics, Inc. recently announced that the US FDA has granted Fast Track designation for the company’s lead product candidate, DTX101, for the treatment of…
West Pharmaceutical Services & Healthprize Technologies Announce Self-Reporting & Barcoding Capabilities for Self-Injection Technology
West Pharmaceutical Services, Inc. and HealthPrize Technologies, LLC, recently announced the completion of the first two phases of their four-phase strategic collaboration. The companies are…
Theravance Biopharma & Mylan Initiate Phase III Program
Theravance Biopharma, Inc. and Mylan N.V. recently announced the initiation of a Phase III program for revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) in…
Lpath Initiates First-in-Human Dosing in Phase I Trial
Lpath, Inc. recently announced that the first cohort of six subjects has been dosed in the Phase I clinical trial with Lpathomab. The double-blind, placebo-controlled,…
EMD Millipore Introduces Enhancements to its EMPROVE® Program
EMD Millipore Introduces Enhancements to its EMPROVE® Program EMD Millipore recently introduced enhancements to its industry-leading EMPROVE portfolio of pharmaceutical raw materials. The expanded documentation…
Science-Based Technology Selection & Formulation Development for Oral Bioavailability Enhancement
Capsugel Dosage Form Solutions White Paper Authors: Hywel Williams, Michael Morgen, Eduardo Jule, Jan Vertommen, Hassan Benameur, Dwayne Friesen and David Vodak Introduction The increasing…
